Santero, a Charleroi, Belgium-based company which is dedicated to the development of antibiotics against multi-drug resistant infections, raised €8M in Series A funding.
The round was led by Newton Biocapital, joined by SFPIM, WE Life Sciences, Sambrinvest and a group of dedicated business angels led by Pierre Drion.
The company intends to use the funds to further develop its first-in-class inhibitors for the treatment of multi-drug resistant infections.
Founded by Cedric Govaerts and Abel Garcia-Pino, Santero is a spin-off company of the Université libre de Bruxelles dedicated to the development of antibiotics against multi-drug resistant infections. Since 2000, only five new classes of antibiotics have been marketed: oxazolidinones, lipopetides, pleuromutilins, tiacumicins and diarylquinolines, but none of them target the Gram-negative bacteria that cause the majority of AMR infections. The company will add a new treatment option for multi-resistant bacteria, improving survival and recovery for patients and providing a solution for society.
FinSMEs
07/06/2023